R1 Announces Alex Mandl Will Not Stand for Re-Election to R1 Board of Directors

Rhea-AI Summary

R1 RCM Inc. (NASDAQ: RCM) announced that Alex Mandl will not seek re-election to its board during the upcoming annual meeting. Mandl has been a board member since 2013, serving as lead director since 2018 and chair of the audit committee since 2015. R1's leadership praised his invaluable contributions to the board. John B. Henneman, III has been appointed as the new lead director, effective immediately. R1 RCM focuses on technology-driven solutions that enhance the patient experience and financial performance for healthcare organizations.

Positive

• John B. Henneman's appointment as lead director may bring a fresh perspective to the board.
• Continuity in governance with an internal candidate stepping into the lead director role.

Negative

• Alex Mandl's departure leaves a potential experience gap in the board's leadership.

MURRAY, Utah, Feb. 07, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), today announced that Alex Mandl informed the company he will not stand for re-election to the R1 board of directors at its next annual meeting of stockholders. Mr. Mandl was elected to the R1 board of directors in 2013 and has served as lead director since 2018 and chair of the audit committee since 2015.

“Alex has been an invaluable voice of experience on the R1 board and a respected advisor for the R1 leadership team,” said Joe Flanagan, president and chief executive officer of R1. “We cannot thank Alex enough for his contributions.”

“We are grateful for the expertise and wisdom that Alex has brought to our board,” said Tony Speranzo, chair of R1’s board of directors. “He led the board during a critical phase of the Company’s growth and he will be greatly missed.”

R1 also announced that John B. Henneman, III, a member of the R1 board of directors since 2016, has been appointed as lead director, effective immediately. Mr. Henneman also serves as chair of the compliance and risk management committee and as a member of the audit committee.

About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Contacts:
R1 RCM
Investor Relations
Atif Rahim
312.324.5476
investorrelations@r1rcm.com

Media Relations
Laura Kelly
312.719.3257 
media@r1rcm.com

 

FAQ

Why is Alex Mandl not seeking re-election to R1's board?

Alex Mandl has informed R1 that he will not stand for re-election at the next annual meeting of stockholders.

Who has been appointed as the new lead director of R1 RCM?

John B. Henneman, III has been appointed as the lead director, effective immediately.

What roles did Alex Mandl hold on R1's board?

Alex Mandl served as lead director since 2018 and chair of the audit committee since 2015.

What is the significance of John B. Henneman's appointment?

John B. Henneman's appointment may ensure continuity in leadership and governance on the board.